StockData
Connect Biopharma Holdings Ltd logo

Connect Biopharma Holdings Ltd (CNTB) stock

CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.58−0.06 (-9.98%)

Close on Nov 17, 2026Market cap $36.45MP/E –Yield –

Connect Biopharma r&d expenses

Research and development expenses are spending on new products and technology.

Connect Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $53.70M, up 75.2% year over year. For fiscal 2025 it was $37.80M, up 29.2% from the year before. The highest annual figure on record is $96.63M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$37.80M+29.2%
FY2024Dec 31, 2024$29.26M-44.8%
FY2023Dec 31, 2023$53.00M-45.1%
FY2022Dec 31, 2022$96.63M+20.0%
FY2021Dec 31, 2021$80.50M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.27M+85.5%
Q1 FY2026Mar 31, 2026$15.03M+126.6%
Q4 FY2025Dec 31, 2025$11.28M+80.9%
Q3 FY2025Sep 30, 2025$11.11M+23.3%
Q2 FY2025Jun 30, 2025$8.77M+64.0%
Q1 FY2025Mar 31, 2025$6.63M-23.4%
Q4 FY2024Dec 31, 2024$6.24M–
Q3 FY2024Sep 30, 2024$9.01M–
Q2 FY2024Jun 30, 2024$5.35M–
Q1 FY2024Mar 31, 2024$8.66M–

More Connect Biopharma figures

See a number that looks wrong?